دورية أكاديمية
Intravenous metoclopramide. An effective antiemetic in cancer chemotherapy.
| العنوان: | Intravenous metoclopramide. An effective antiemetic in cancer chemotherapy. |
|---|---|
| المؤلفون: | Strum SB, McDermed JE, Opfell RW, Riech LP |
| المصدر: | JAMA [JAMA] 1982 May 21; Vol. 247 (19), pp. 2683-6. |
| نوع المنشور: | Clinical Trial; Controlled Clinical Trial; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Medical Association Country of Publication: United States NLM ID: 7501160 Publication Model: Print Cited Medium: Print ISSN: 0098-7484 (Print) Linking ISSN: 00987484 NLM ISO Abbreviation: JAMA Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Chicago : American Medical Association, 1960- |
| مواضيع طبية MeSH: | Antineoplastic Agents/*adverse effects , Metoclopramide/*administration & dosage , Nausea/*prevention & control , Vomiting/*prevention & control, Adult ; Aged ; Antineoplastic Agents/administration & dosage ; Cisplatin/administration & dosage ; Cisplatin/adverse effects ; Clinical Trials as Topic ; Drug Therapy, Combination ; Female ; Humans ; Infusions, Parenteral ; Male ; Middle Aged ; Nausea/chemically induced ; Vomiting/chemically induced |
| مستخلص: | An open-label clinical trial was conducted to test the safety and efficacy of intravenous metoclopramide monohydrochloride in preventing chemotherapy-induced nausea and vomiting. Thirty-eight patients received a total of 83 assessable courses of chemotherapy with cisplatin alone or in combination with other cytotoxic agents. In 19 of 38 patients (50%) or 40 of 83 courses (48%), nausea or vomiting did not occur ("total protection") and in six of 38 patients (16%) or 19 of 83 courses (23%), emesis occurred one of two times ("major protection"). Thus, 25 of 38 patients (66%) receiving 59 of 83 courses (71%) of cisplatin-containing chemotherapy attained either total or major antiemetic protection with metoclopramide. In those patients who received multiple courses of chemotherapy, antiemetic protection afforded by metoclopramide remained unabated. At this dosage, the drug was well tolerated with minimal side effects. Intravenous metoclopramide is consistently effective in preventing emesis associated with cisplatin when used either alone or in combination with other cancer chemotherapy agents that are in themselves emetogenic. |
| المشرفين على المادة: | 0 (Antineoplastic Agents) L4YEB44I46 (Metoclopramide) Q20Q21Q62J (Cisplatin) |
| تواريخ الأحداث: | Date Created: 19820521 Date Completed: 19820722 Latest Revision: 20190630 |
| رمز التحديث: | 20240627 |
| DOI: | 10.1001/jama.247.19.2683 |
| PMID: | 7043002 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 0098-7484 |
|---|---|
| DOI: | 10.1001/jama.247.19.2683 |